Differentiating tunnel and abscess/inflammatory nodule recurrence refines surgical outcomes after wide excision in patients ...
The sequence of chemotherapy and anti-PD-1 antibody influence the efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell cancer: A phase II study. This is an ASCO ...
Please provide your email address to receive an email when new articles are posted on . A healthy sleep pattern, as well as improving sleep habits, were associated with a lower risk for atrial ...
This is an ASCO Meeting Abstract from the ASCO Breakthrough: A Global Summit for Oncology Innovators. This abstract does not include a full text component.
The ZEST trial, a phase 3 study on MRD-guided therapy in breast cancer, was terminated early due to low randomization rates. ctDNA was most frequently detected within six months post-treatment, ...
Nonresponders to UTUC neoadjuvant chemo have more aggressive recurrence patterns that may have important surveillance and treatment implications. Patients with node-positive disease after neoadjuvant ...
Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...
Nearly half of advanced ovarian cancer patients relapsed after first-line PARP inhibitor maintenance, emphasizing the need for refined postrecurrence strategies. BRCA mutation carriers were more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback